- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06388070
To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye Syndrome
A Multicenter, Randomized, Double-blinded, Non-inferiority Phase 3 Study to Evaluate the Efficacy and Safety of HUC3-053 Compared With Hyalein Mini Eye Drops in Patients With Dry Eye Syndrome
This is a multi-center, randomized, double-blinded, non-inferiority study to evluate the efficacy and safety of HUC3-053 in patients with dry eye syndrome.
After a 2-week run-in period, patients will be randomized equally to the HUC3-053 or Hyalein Mini Drops administered bilaterally five to six times a day for 12 weeks.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multi-center, randomized, double-blinded, non-inferiority study to evluate the efficacy and safety of HUC3-053 in patients with dry eye syndrome.
During a 2-week study run-in period prior to randomization, all subjects will receive rescue drug bilaterally up to 4 times a day. Randomization will then occur as 1:1 where patients will be assigned to receive HUC3-053 or Hyalein Mini Drops given bilaterally five to six times a day. The treatment period is 12 weeks.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Hee Jung Yang
- Phone Number: +82-70-7492-6054
- Email: hjyang@huons.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age over 19
- Volunteer who have had more than one symptom of dry eye disease for at least 3 month before screening visit.
- Corneal staining score(Oxford grading) ≥ 2 and Schirmer test ≤ 10mm/5min (If Schirmer test = 0mm/5min, Nasal stimulation schirmer test ≥ 3mm/5min) and TBUT test ≤10 and OSDI (Ocular Surface Disease Index) ≥ 23 in at least one of both eyes
- Best corrected visual acuity ≥ 0.2 in both eyes at Screening and Randomization Visit
Exclusion Criteria:
- The patients with clinically significant ocular disorders affected the test result Current or recent patients used dry eye syndrome medications (topical or systemic) that may affect the status
- SBP ≥140mmHg or DBP ≥ 90mmHg or HbA1c>9%
- Wearing contact lenses within 72 hr of screening visit
- Pregnancy or Breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HUC3-053
Participants received "HUC3-053" drops in each eye five to six times a day for 12 weeks.
|
drops in each eye five to six times a day for 12 weeks
Other Names:
|
Active Comparator: Hyalein Mini Drops
Participants received "Hyalein Mini Drops" in each eye five to six times a day for 12 weeks.
|
drops in each eye five to six times a day for 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Corneal staining score
Time Frame: Week 12
|
Change from Baseline in Corneal staining score at week 12
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Corneal staining score
Time Frame: Week 4, 8
|
Change from Baseline in Corneal staining score at week 4, 8
|
Week 4, 8
|
Change from Baseline in Conjunctival staining score
Time Frame: Week 4, 8, 12
|
Change from Baseline in Conjunctival staining score at week 4, 8, 12
|
Week 4, 8, 12
|
Change from Baseline in Schirmer test
Time Frame: Week 4, 8, 12
|
Change from Baseline in Schirmer test at week 4, 8, 12
|
Week 4, 8, 12
|
Change from Baseline in Tear film break-up time
Time Frame: Week 4, 8, 12
|
Change from Baseline in Tear film break-up time at week 4, 8, 12
|
Week 4, 8, 12
|
Change from Baseline in Ocular surface disease index
Time Frame: Week 4, 8, 12
|
Change from Baseline in Ocular surface disease index at week 4, 8, 12
|
Week 4, 8, 12
|
Change from Baseline in Soreness after eye drop assessed by NRS
Time Frame: Week 4, 8, 12
|
Change from Baseline in Soreness after eye drop assessed by NRS at week 4, 8, 12
|
Week 4, 8, 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chul Young Choi, Gangbuk Samsung Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUC3-053
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Syndromes
-
Singapore National Eye CentreCompleted
-
Singapore National Eye CentreCompleted
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
OptovueCompleted
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Johnson & Johnson Vision Care, Inc.Completed
-
He Eye HospitalCompleted
Clinical Trials on HUC3-053
-
Double Bond Pharmaceutical ABNot yet recruiting
-
Johnson & Johnson Consumer and Personal Products...CompletedAtopic DermatitisUnited States